Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Recruiting now · Phase 3

Conditions studied: Prostate Cancer Metastatic

In brief

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.

Key facts

Study ID: NCT06136624
Run by: Merck Sharp & Dohme LLC
People needed: 1310
Starts: 2023-12-31
Expected to finish: 2030-02-15
Last updated by the study team: 2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<1.7 nM)
Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment
Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment
If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression >4 weeks since the last flutamide treatment and >6 weeks since the last bicalutamide or nilutamide treatment
Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization
Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on antiretroviral therapy (ART)
Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening.
Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom

You may not qualify if…

Has a gastrointestinal disorder that might affect absorption
Has a history of pituitary dysfunction
Has poorly controlled diabetes mellitus
Has clinically significant abnormal serum potassium or sodium level
Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization
Has a history of clinically significant ventricular arrhythmias
Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization
Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications
Participants who have not adequately recovered from major surgery or have ongoing surgical complications
Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization
Has received radium-223 or Lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or Lutetium-177 administered more than 4 weeks before the date of randomization
Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization
Has received colony-stimulating factors within 28 days before the date of randomization
Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and platelet transfusions are acceptable if not given within 28 days of the date of randomization
Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks
Has a "superscan" bone scan
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has an active infection requiring systemic therapy
Has concurrent active HBV or known active HCV infection
Has a history of long QTc syndrome
Has any of the following at Screening Visit: hypotension (systolic BP <110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy)

Where it is running

Avera Cancer Institute - Pierre ( Site 0118) — Pierre, South Dakota, United States (enrolling)
Avera Cancer Institute - Yankton ( Site 0117) — Yankton, South Dakota, United States (enrolling)
University Hospitals Cleveland Medical Center ( Site 0043) — Cleveland, Ohio, United States (enrolling)
VA Portland Health Care System ( Site 0058) — Portland, Oregon, United States (enrolling)
Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California, United States (enrolling)
Avera Cancer Institute- Research ( Site 0094) — Sioux Falls, South Dakota, United States (enrolling)
Anschutz Cancer Pavilion ( Site 0046) — Aurora, Colorado, United States (enrolling)
James J. Peters VA Medical Center ( Site 0088) — The Bronx, New York, United States (enrolling)
University of Colorado Health - Highlands Ranch Hospital ( Site 0111) — Highlands Ranch, Colorado, United States (enrolling)
Stanford Cancer Center ( Site 0036) — Palo Alto, California, United States (enrolling)
University of Illinois at Chicago ( Site 0105) — Chicago, Illinois, United States (enrolling)
University of Chicago Medical Center ( Site 0045) — Chicago, Illinois, United States (enrolling)
University of Iowa ( Site 0047) — Iowa City, Iowa, United States (enrolling)
University of Colorado Health - Lone Tree Medical Center ( Site 0112) — Lone Tree, Colorado, United States (enrolling)
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) — New Haven, Connecticut, United States (enrolling)
Baltimore Veterans Affairs Medical Center ( Site 0069) — Baltimore, Maryland, United States (enrolling)
Greenebaum Comprehensive Cancer Center ( Site 0049) — Baltimore, Maryland, United States (enrolling)
Florida Cancer Specialists - South ( Site 7003) — Fort Myers, Florida, United States (enrolling)
M Health Fairview Clinics and Surgery Center ( Site 0019) — Minneapolis, Minnesota, United States (enrolling)
Metro-Minnesota Community Clinical Oncology ( Site 0014) — Saint Louis Park, Minnesota, United States (enrolling)
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051) — Miami, Florida, United States (enrolling)
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095) — Omaha, Nebraska, United States (enrolling)
Comprehensive Cancer Centers of Nevada ( Site 0010) — Las Vegas, Nevada, United States (enrolling)
Atlantic Health System Morristown Medical Center ( Site 0115) — Morristown, New Jersey, United States (enrolling)
SCRI Oncology Partners ( Site 7000) — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.